Department of Neurosurgery, Nuclear Industry 215 Hospital of Shaanxi Province, 712000, China.
Department of Neurosurgery, Xianyang Hospital of Yan'an University, 712000, China; Center of Excellence in Electrochemistry, School of Chemistry, College of Science, University of Tehran, Tehran, 14155-6455, Iran.
J Nanosci Nanotechnol. 2021 Feb 1;21(2):1202-1211. doi: 10.1166/jnn.2021.18668.
In order to explore the influence of nanoparticle-loaded edaravone on postoperative effects in patients with cerebral hemorrhage, a total of 120 patients who were diagnosed as cerebral hemorrhage and underwent minimally invasive hematoma removal at the designated hospital by the study from December 2014 to December 2018 were selected as research objects and divided into three groups according to the random number table method: edaravone treatment (ET) group, nanoparticle-loaded edaravone treatment (NET) group, and combined treatment (CT) group with 40 patients in each group. Three groups of patients underwent routine treatments based on their conditions, including regulating blood sugar, regulating blood pressure, anti-infection, nutritional support, and managing complications, in which 25 mg edaravone injection and 100 ml saline were added for patients in NET and CT group on the basis of the routine treatment of patients in ET group. The results showed that, after 15 days of standard treatment, the 40 patients in NET group had significantly improved neurological function than that before the treatment; the secretion of inflammatory factors in peripheral serum increased on the 7th day of treatment and decreased on the 14th day of treatment; there was no statistically significant difference in edema volume before treatment and the edema volume in the NET group was (11.56±0.44) mL after treatment, which was significantly smaller than that in ET group of (14.63±1.15) mL and the difference between the three groups was statistically significant ( <0.05). Therefore, it is believed that nanoparticle-loaded edaravone has an important effect on the postoperative effect of patients with cerebral hemorrhage; it can significantly improve the neurological function of patients with cerebral hemorrhage after minimally invasive drainage, and obviously reduce the production and release of interleukin and tumor necrosis factor, which is beneficial to protect healthy brain tissue and other organs throughout the body, and is conducive to the recovery and healing of cerebral hemorrhage. The results of this study provide a reference for further research on the influence of nanoparticle-loaded edaravone on postoperative effects in patients with cerebral hemorrhage.
为了探讨载纳米粒依达拉奉对脑出血患者术后效果的影响,选取 2014 年 12 月至 2018 年 12 月在指定医院接受微创血肿清除术的脑出血患者 120 例为研究对象,采用随机数字表法将其分为依达拉奉治疗(ET)组、载纳米粒依达拉奉治疗(NET)组和联合治疗(CT)组,每组 40 例。三组患者均根据病情进行常规治疗,包括血糖调节、血压调节、抗感染、营养支持和并发症管理,在 ET 组常规治疗的基础上,NET 和 CT 组患者分别加入 25mg 依达拉奉注射液和 100ml 生理盐水。结果显示,NET 组患者在经过 15 天的标准治疗后,神经功能较治疗前明显改善;治疗第 7 天外周血清中炎症因子分泌量增加,第 14 天开始下降;治疗前水肿体积无统计学差异,NET 组治疗后水肿体积为(11.56±0.44)mL,明显小于 ET 组的(14.63±1.15)mL,三组间差异有统计学意义(<0.05)。由此可见,载纳米粒依达拉奉对脑出血患者术后效果具有重要影响,能明显改善微创引流术后脑出血患者的神经功能,明显减少白细胞介素和肿瘤坏死因子的产生和释放,有利于保护全身其他健康脑组织和器官,有利于脑出血的恢复和愈合。本研究结果为进一步研究载纳米粒依达拉奉对脑出血患者术后效果的影响提供了参考。